Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis

被引：0
|
作者：
Preblick, Ronald [1 ]
Gray, Cori [1 ]
Ali, Talaha [1 ]
DasMahapatra, Pronabesh [1 ]
机构：
[1] Sanofi Genzyme, Cambridge, MA 02142 USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2020年 / 26卷 / 09期
关键词：
D O I：
10.18553/jmcp.2020.26.9.1177
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：1177 / 1177
页数：1
相关论文
共 50 条
  • [1] Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review
    Park, Young-Shil
    Yoo, Ki-Young
    Park, Sang Kyu
    Hwang, Taiju
    Jung, Aeran
    Choi, Eun Jin
    BLOOD RESEARCH, 2024, 59 (01)
  • [2] HIV positive patient with severe hemophilia A and malignant lymphoma: prophylaxis with recombinant fviii
    Geierova, V
    Pohlreichova, V
    Rittich, S.
    Benesova, K.
    Hrachovinova, I., V
    Cetkovsky, P.
    Salaj, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 516 - 516
  • [3] CHIEF: A retrospective self-control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis
    Mashiach, Daniel
    Mead, Patrice
    Carneiro, Kendall
    Malvar, Jemily
    Knight, Susan
    Young, Guy
    PEDIATRIC BLOOD & CANCER, 2024, 71 (12)
  • [4] Multicenter retrospective and prospective analysis of emicizumab and FVIII prophylaxis in children with severe hemophilia A
    Hassan, Tamer
    Lotfy, Gehan
    Elalfy, Omar
    Amin, Mervat
    Elmasry, Zahraa
    Elhawary, Eslam
    Darwish, Ahmed
    Elalfy, Mohsen
    HAEMOPHILIA, 2024, 30 : 222 - 223
  • [5] The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study
    Yao, Wanru
    Xiao, Juan
    Cheng, Xiaoling
    Feng, Guoshuang
    Li, Changgang
    Zhang, Xinsheng
    Hu, Qun
    Xu, Weiqun
    Sun, Jing
    Yang, Renchi
    Li, Xiaojing
    Zhou, Rongfu
    Lian, Shimei
    Gu, Jian
    Wu, Junde
    Zhao, Yongqiang
    Wu, Runhui
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (07) : 851 - 858
  • [6] RETROSPECTIVE ANALYSIS OF RVIII-SINGLECHAIN AND OTHER COMMONLY USED RECOMBINANT FVIII PRODUCTS COMPARING PROPHYLAXIS TREATMENT REGIMENS AND ASSOCIATED CLINICAL OUTCOMES IN HAEMOPHILIA A PATIENTS IN ITALY
    Mancuso, M. E.
    Santoro, C.
    Maro, G.
    Sommerer, P.
    HAEMOPHILIA, 2021, 27 : 122 - 123
  • [7] The pharmacokinetics characteristics of plasma-derived and recombinant FVIII products in Chinese children with severe hemophilia A
    Chen, Zhenping
    Li, Peijing
    Cheng, Xiaoling
    Tang, Ling
    Li, Gang
    Zhen, Yingzi
    Wu, Xinyi
    Wu, Runhui
    HAEMOPHILIA, 2016, 22 : 101 - 101
  • [8] Comparing Factor Use and Bleed Rates in US Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products
    Simpson, Mindy L.
    Desai, Vidhi
    Maro, Geraldine S.
    Yan, Songkai
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (04): : 504 - 512
  • [9] Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review
    Rahim, SA
    Panju, A
    Pai, M
    Ginsberg, J
    THROMBOSIS RESEARCH, 2003, 111 (4-5) : 215 - 219
  • [10] Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A
    Dargaud, Yesim G.
    Klamroth, Robert
    Rusen, Luminita
    Windyga, Jerzy
    Bichler, Johann
    Knaub, Sigurd
    Negrier, Claude
    BLOOD, 2016, 128 (22)
12345